ClinicalTrials.gg
TerminatedNCT04804033Updated Mar 27, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

A Phase 2/3 interventional study of BHV-3500 (zavegepant) and Placebo in Migraine, sponsored by Pfizer. Terminated at 116 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Pfizer · Phase 2/3, Interventional, and Prevention

Why this study was terminated
Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,753
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.

Enrollment
3rd of 12
1,753 · median 225
Started
2021
the only one that year
Phase 2/3
3 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 2/3, and was the 4th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About zavegepant

zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing zavegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

03

Conditions studied

  • Migraine

Keywords

  • Migraine Prevention
  • Phonophobia
  • Photophobia
  • Nausea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of

Headache Disorders, 3rd Edition, including the following:

  1. Age of onset of migraines prior to 50 years of age
  2. Migraine attacks, on average, lasting 4 - 72 hours if untreated
  3. Per subject report, at least 15 headache days per month, at lest 8 migraine days per month, and at least 1 headache-free day per month within the last 3 months prior to the Screening Visit
  4. Eight or more migraine days during the Observation Period
  5. 15 or more headache days during the Observation Period
  6. One or more non-headache days during the Observation Period
  7. Ability to distinguish migraine attacks from tension/cluster headaches
  8. Subjects on prophylactic migraine medication are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change during the course of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject with a history of disease
  2. Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening
  3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to screening).
  4. Subjects with major depressive episode or anxiety disorder which require more than 1 daily medication for each disorder or subjects with a major depressive episode within the last 12 months. Medications to treat major depressive disorder or an anxiety disorder must have been at a stable dose for at least 3 months prior to the Screening Visit.
  5. Subjects with active chronic pain syndromes, other pain syndromes (including trigeminal neuralgia), psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion interfere with study assessments of safety or efficacy.
  6. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease or condition (e.g. chronic pancreatitis, ulcerative colitis, etc.) that causes malabsorption.
  7. > 33 kg/m2
  8. History of gallstones or cholecystectomy.
  9. The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspected infection, or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,753 participants (actual)

Study arms

  • Active comparator
    BHV-3500 200mg

    Zavegepant 200mg oral soft gel capsule.

    Drug: BHV-3500 (zavegepant)

  • Placebo comparator
    Placebo 200mg

    Matching placebo 200mg oral soft gel capsule.

    Drug: Placebo

  • Active comparator
    BHV-3500 100mg

    Zavegepant 100mg oral soft gel capsule.

    Drug: BHV-3500 (zavegepant)

  • Placebo comparator
    Placebo 100mg

    Matching placebo 100mg oral soft gel capsule.

    Drug: Placebo

Interventions

  • BHV-3500 (zavegepant) softgel capsule.

  • DrugPlacebo

    Matching placebo softgel capsule.

06

What researchers measure

Primary outcomes

  1. Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

    A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period).

    Time frame: Observation Phase: 28 days prior to randomization and baseline; Entire DBT Phase: 12 weeks (Week 1 through 12)

Secondary outcomes

  1. Percentage of Participants With >= 50 % Reduction in Number of Moderate to Severe Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

    A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of following criteria (A and/or B): A. \>=2 of following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period).

    Time frame: Entire DBT Phase: 12 weeks (Week 1 through 12)

  2. Mean Change From Observation Phase in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase

    A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A.\>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 9 to 12\])/(total number of eDiary efficacy data days in the month\[Week 9 to 12\]).

    Time frame: Observation Phase: 28 days prior to randomization and baseline; DBT Phase: last 4 weeks (Week 9 through 12)

  3. Mean Change From Observation Phase in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase

    A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 1 to 4\])/ (total number of eDiary efficacy data days in the month\[Week 1 to 4\]).

    Time frame: Observation Phase: 28 days prior to randomization and baseline; DBT Phase: first 4 weeks (Week 1 through 4)

  4. Mean Number of Acute Migraine -Specific Medication Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

    Acute migraine (AM)-specific medication day was defined as any calendar day on which the participant took an acute migraine-specific medication during aura or to treat a headache. Acute migraine-specific medications were triptans and ergotamine. The number of acute migraine-specific medication days per month were prorated to 28 days and derived as follows: 28 \* (total number of acute migraine-specific medication days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period).

    Time frame: Entire DBT Phase: 12 weeks (Week 1 through 12)

  5. Mean Change From Baseline in the Migraine-specific Quality of Life Questionnaire (MSQ) v 2.1 Restrictive Role Function Domain Score at Week 12

    MSQ v 2.1 is 14-item questionnaire that assessed impact of treatment on participant-reported quality of life across 3 domains: role function-restrictive, preventive, and emotional function. Restrictive role function domain consists of 7 items that describe how migraine limits one's daily social, work-related activities. Participants respond to items using a 6-point scale ranging from 1 (none of the time) to 6 (all of the time), which are assigned scores of 1 to 6, respectively. Response from each item of restrictive role function domain were added providing a possible raw score range of 7 (no impairment) to 42 (maximum impairment). Raw score range of restrictive role function domain was then transformed to a 0 (no impairment) to 100 (maximum impairment), higher scores = higher impairment.

    Time frame: DBT Phase: Baseline (before dose on Day 1), Week 12

  6. Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12

    MIDAS is a retrospective, participant-reported, 5-item questionnaire that measured headache related disability as lost days due to headache from paid work or school, household work and non-work activities over past 3-months. The total score is calculated as the sum of item scores to all 5 questions on a scale of 0 (no disability) to 90 (maximum disability) resulting into overall possible MIDAS total score (range from 0 (no disability) to 450 (maximum disability). Higher scores = more severe disability.

    Time frame: DBT Phase: Baseline (before dose on Day 1), Week 12

  7. Number of Participants With Moderate or Severe Adverse Events (AEs): DBT Phase

    AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

    Time frame: DBT Phase: During 12 weeks of treatment

  8. Number of Participants With Serious Adverse Events (SAEs): DBT Phase

    AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

    Time frame: DBT Phase: During 12 weeks of treatment

  9. Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

    Time frame: DBT Phase: During 12 weeks of treatment

  10. Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: DBT Phase

    Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: DBT: During 12 weeks of treatment

  11. Number of Participants With Moderate or Severe AEs: OLE Phase

    AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

    Time frame: OLE: During 52 weeks of treatment

  12. Number of Participants With SAEs: OLE Phase

    AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

    Time frame: OLE: During 52 weeks of treatment

  13. Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

    Time frame: OLE: During 52 weeks of treatment

  14. Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: OLE Phase

    Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: OLE: During 52 weeks of treatment

  15. Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: DBT Phase

    Elevations of AST or alanine aminotransferase (ALT) \> 3 \*upper limit of normal (ULN) concurrent with total bilirubin (TBL) \> 2 \*ULN (elevations on the same laboratory collection date) were included.

    Time frame: DBT: Over 12 weeks of treatment

  16. Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: OLE Phase

    Elevations of AST or ALT \> 3 \* ULN concurrent with TBL \> 2 \*ULN were defined as elevations on the same collection date.

    Time frame: OLE: Over 52 weeks of treatment

  17. Number of Participants With Hepatic-related AEs by Intensity: DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

    Time frame: DBT Phase: During 12 weeks of treatment

  18. Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

    Time frame: DBT Phase: During 12 weeks of treatment

  19. Number of Participants With Hepatic-related AEs by Intensity: OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

    Time frame: OLE: Over 52 weeks of treatment

  20. Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

    Time frame: OLE: Over 52 weeks of treatment

07

Results

Posted Mar 27, 2025

Participant flow

Period 1: DBT Phase
Participant flow — Period 1: DBT Phase
MilestoneZavegepant 100 mg (OLE/DBT)Zavegepant 200 mg (OLE/DBT)Placebo (DBT)/ Zavegepant 100 mg (OLE)Placebo (DBT)/ Zavegepant 200 mg (OLE)
Started1781808888
Treated1731758688
Completed1441346964
Not completed34461924
Withdrew: Adverse event1534
Withdrew: Death1000
Withdrew: Lost to follow-up3713
Withdrew: Non-compliance1012
Withdrew: Other0100
Withdrew: Pregnancy2000
Withdrew: Study terminated by sponsor151659
Withdrew: Withdrawal by subject61276
Withdrew: Randomized but not treated5520
Period 2: OLE Phase
Participant flow — Period 2: OLE Phase
MilestoneZavegepant 100 mg (OLE/DBT)Zavegepant 200 mg (OLE/DBT)Placebo (DBT)/ Zavegepant 100 mg (OLE)Placebo (DBT)/ Zavegepant 200 mg (OLE)
Started105945049
Treated105945049
Completed34342217
Not completed71602832
Withdrew: Adverse event3420
Withdrew: Lost to follow-up8434
Withdrew: Non-compliance2201
Withdrew: Other0200
Withdrew: Physician decision1100
Withdrew: Pregnancy0020
Withdrew: Study terminated by sponsor41371719
Withdrew: Withdrawal by subject16837
Withdrew: Not reported0200
Withdrew: Failure to meet continuation criteria0011
Period 3: Follow-up Phase
Participant flow — Period 3: Follow-up Phase
MilestoneZavegepant 100 mg (OLE/DBT)Zavegepant 200 mg (OLE/DBT)Placebo (DBT)/ Zavegepant 100 mg (OLE)Placebo (DBT)/ Zavegepant 200 mg (OLE)
Started1541624748
Completed1241314138
Not completed3031610
Withdrew: Lost to follow-up5901
Withdrew: Other0121
Withdrew: Withdrawal by subject7634
Withdrew: Not reported181514

Outcome measures

PrimaryMean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period).

Time frame:
Observation Phase: 28 days prior to randomization and baseline; Entire DBT Phase: 12 weeks (Week 1 through 12)
Reported as:
Least squares mean · Migraine Days per Month
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
Migraine Days per MonthZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo Pooled (DBT)
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)-7.0 (-8.10 to -5.92)-6.3 (-7.45 to -5.10)-5.6 (-6.80 to -4.37)
Statistical analysis
  • Zavegepant 100 mg (DBT) vs Placebo Pooled (DBT) · Difference in least square mean (lsm): -1.4 · 97.5% CI -2.72 to -0.12Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
  • Zavegepant 200 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: -0.7 · 97.5% CI -2.07 to 0.69Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
SecondaryPercentage of Participants With >= 50 % Reduction in Number of Moderate to Severe Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of following criteria (A and/or B): A. \>=2 of following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived as follows: 28\*(total number of migraine days through Month 3\[Weeks 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3\[Weeks 1 to 12\] in on-DBT efficacy analysis period).

Time frame:
Entire DBT Phase: 12 weeks (Week 1 through 12)
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 50 % Reduction in Number of Moderate to Severe Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
Percentage of participantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo Pooled (DBT)
Percentage of Participants With >= 50 % Reduction in Number of Moderate to Severe Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)56.1 (47.7 to 65.1)46.6 (37.8 to 55.4)40.0 (31.4 to 48.5)
Statistical analysis
  • Zavegepant 100 mg (DBT) vs Placebo Pooled (DBT) · Difference in percentage: 16.6 · 97.5% CI 4.4 to 28.8Stratified by randomization stratum using Mantel-Haenszel risk estimation.
  • Zavegepant 200 mg (DBT) vs Placebo Pooled (DBT) · Difference in percentage: 6.6 · 97.5% CI -5.6 to 18.9Stratified by randomization stratum using Mantel-Haenszel risk estimation.
SecondaryMean Change From Observation Phase in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase

A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A.\>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 9 to 12\])/(total number of eDiary efficacy data days in the month\[Week 9 to 12\]).

Time frame:
Observation Phase: 28 days prior to randomization and baseline; DBT Phase: last 4 weeks (Week 9 through 12)
Reported as:
Least squares mean · Migraine Days per Month
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase
Migraine Days per MonthZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo Pooled
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase-7.8 (-9.11 to -6.59)-7.2 (-8.56 to -5.83)-6.8 (-8.22 to -5.38)
Statistical analysis
  • Zavegepant 100 mg (DBT) vs Placebo Pooled · Difference in lsm: -1 · 97.5% CI -2.68 to 0.58Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
  • Zavegepant 200 mg (DBT) vs Placebo Pooled · Difference in lsm: -0.4 · 97.5% CI -2.10 to 1.31Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
SecondaryMean Change From Observation Phase in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase

A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) B. \>= 1 of the following associated symptoms: a. Nausea and/or vomiting b. Photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period as follows: 28\* (total number of migraine days in the month\[Week 1 to 4\])/ (total number of eDiary efficacy data days in the month\[Week 1 to 4\]).

Time frame:
Observation Phase: 28 days prior to randomization and baseline; DBT Phase: first 4 weeks (Week 1 through 4)
Reported as:
Least squares mean · Migraine Days per Month
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase
Migraine Days per MonthZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo Pooled (DBT)
Mean Change From Observation Phase in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase-5.7 (-6.89 to -4.51)-5.1 (-6.26 to -3.87)-3.9 (-5.10 to -2.72)
Statistical analysis
  • Zavegepant 100 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: -1.8 · 97.5% CI -3.16 to -0.42Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
  • Zavegepant 200 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: -1.2 · 97.5% CI -2.53 to 0.22Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
SecondaryMean Number of Acute Migraine -Specific Medication Days Per Month Over Entire DBT Phase (Weeks 1 to 12)

Acute migraine (AM)-specific medication day was defined as any calendar day on which the participant took an acute migraine-specific medication during aura or to treat a headache. Acute migraine-specific medications were triptans and ergotamine. The number of acute migraine-specific medication days per month were prorated to 28 days and derived as follows: 28 \* (total number of acute migraine-specific medication days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period)/ (total number of eDiary efficacy data days through Month 3 \[Week 1 to 12\] in the on-DBT efficacy analysis period).

Time frame:
Entire DBT Phase: 12 weeks (Week 1 through 12)
Reported as:
Least squares mean · AM-specific Medication Days per Month
Mean Number of Acute Migraine -Specific Medication Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
AM-specific Medication Days per MonthZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo Pooled (DBT)
Mean Number of Acute Migraine -Specific Medication Days Per Month Over Entire DBT Phase (Weeks 1 to 12)2.4 (1.43 to 3.43)3.0 (1.91 to 4.17)3.2 (1.94 to 4.46)
Statistical analysis
  • Zavegepant 100 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: -0.8 · 97.5% CI -1.59 to 0.05Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
  • Zavegepant 200 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: -0.2 · 97.5% CI -1.06 to 0.74Linear mixed effects model with repeated measures with number of total migraine days per month in the OP as covariate, treatment group, randomization stratum, month, month-by treatment group interaction as fixed effects using migraine analysis set.
SecondaryMean Change From Baseline in the Migraine-specific Quality of Life Questionnaire (MSQ) v 2.1 Restrictive Role Function Domain Score at Week 12

MSQ v 2.1 is 14-item questionnaire that assessed impact of treatment on participant-reported quality of life across 3 domains: role function-restrictive, preventive, and emotional function. Restrictive role function domain consists of 7 items that describe how migraine limits one's daily social, work-related activities. Participants respond to items using a 6-point scale ranging from 1 (none of the time) to 6 (all of the time), which are assigned scores of 1 to 6, respectively. Response from each item of restrictive role function domain were added providing a possible raw score range of 7 (no impairment) to 42 (maximum impairment). Raw score range of restrictive role function domain was then transformed to a 0 (no impairment) to 100 (maximum impairment), higher scores = higher impairment.

Time frame:
DBT Phase: Baseline (before dose on Day 1), Week 12
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the Migraine-specific Quality of Life Questionnaire (MSQ) v 2.1 Restrictive Role Function Domain Score at Week 12
Scores on a scaleZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo Pooled (DBT)
Mean Change From Baseline in the Migraine-specific Quality of Life Questionnaire (MSQ) v 2.1 Restrictive Role Function Domain Score at Week 1224.5 (19.10 to 29.83)20.6 (14.63 to 26.61)20.5 (14.92 to 26.12)
Statistical analysis
  • Zavegepant 100 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: 3.9 · 97.5% CI -1.50 to 9.39Linear regression model had the following variables: Week 12 change from baseline in domain score as the dependent variable; baseline domain score as a covariate; treatment group and randomization stratum as fixed effects.
  • Zavegepant 200 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: 0.1 · 97.5% CI -5.66 to 5.86Linear regression model had the following variables: Week 12 change from baseline in domain score as the dependent variable; baseline domain score as a covariate; treatment group and randomization stratum as fixed effects.
SecondaryMean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12

MIDAS is a retrospective, participant-reported, 5-item questionnaire that measured headache related disability as lost days due to headache from paid work or school, household work and non-work activities over past 3-months. The total score is calculated as the sum of item scores to all 5 questions on a scale of 0 (no disability) to 90 (maximum disability) resulting into overall possible MIDAS total score (range from 0 (no disability) to 450 (maximum disability). Higher scores = more severe disability.

Time frame:
DBT Phase: Baseline (before dose on Day 1), Week 12
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12
Scores on a scaleZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo Pooled (DBT)
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12-26.8 (-35.81 to -17.79)-27.1 (-36.62 to -17.61)-17.9 (-31.36 to -4.34)
Statistical analysis
  • Zavegepant 100 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: -9 · 97.5% CI -18.10 to 0.19Linear regression model had the following variables: Week 12 change from baseline in domain score as the dependent variable; baseline domain score as a covariate; treatment group and randomization stratum as fixed effects.
  • Zavegepant 200 mg (DBT) vs Placebo Pooled (DBT) · Difference in lsm: -9.3 · 97.5% CI -18.95 to 0.41Linear regression model had the following variables: Week 12 change from baseline in domain score as the dependent variable; baseline domain score as a covariate; treatment group and randomization stratum as fixed effects.
SecondaryNumber of Participants With Moderate or Severe Adverse Events (AEs): DBT Phase

AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

Time frame:
DBT Phase: During 12 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Moderate or Severe Adverse Events (AEs): DBT Phase
ParticipantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)
Number of Participants With Moderate or Severe Adverse Events (AEs): DBT Phase20254513922
SecondaryNumber of Participants With Serious Adverse Events (SAEs): DBT Phase

AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

Time frame:
DBT Phase: During 12 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs): DBT Phase
ParticipantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)
Number of Participants With Serious Adverse Events (SAEs): DBT Phase112011
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

Time frame:
DBT Phase: During 12 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase
ParticipantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)
Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase257347
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Test Abnormalities: DBT Phase

Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
DBT: During 12 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: DBT Phase
ParticipantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)
Hemoglobin011000
Creatine Kinase5712101
LDL Cholesterol7613257
LDL Cholesterol, fasting415134
LDL Cholesterol, not fasting033011
Potassium, high000303
Triglycerides101000
Urinalysis101000
SecondaryNumber of Participants With Moderate or Severe AEs: OLE Phase

AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. AEs included both SAEs and all non-SAEs. Severity: Moderate=Alleviated with additional specific therapeutic intervention, interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe= Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

Time frame:
OLE: During 52 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Moderate or Severe AEs: OLE Phase
ParticipantsZavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)
Number of Participants With Moderate or Severe AEs: OLE Phase2937
SecondaryNumber of Participants With SAEs: OLE Phase

AEs: new untoward medical occurrence or worsening of a pre-existing medical condition in participant or clinical investigation participant administered investigational product that does not necessarily have a causal relationship with treatment. SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

Time frame:
OLE: During 52 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With SAEs: OLE Phase
ParticipantsZavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)
Number of Participants With SAEs: OLE Phase13
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

Time frame:
OLE: During 52 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase
ParticipantsZavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)
Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase24
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Test Abnormalities: OLE Phase

Laboratory tests included eosinophils, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets; albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, bilirubin, calcium, cholesterol, potassium, sodium, triglycerides, uric acid, urinalysis, urine protein, creatine kinase (CK), creatinine, glomerular filtration rate (GFR), glucose, glucose fasting, lactate dehydrogenase, low density lipoprotein (LDL) Cholesterol, LDL Cholesterol. Number of participants with grade 3 to 4 laboratory test abnormalities were evaluated in this outcome measure. Only rows which included at least 1 participant in any reporting group with grade 3 to 4 abnormality were reported in this outcome measure. As per Common Terminology Criteria for Adverse Events (CTCAE version 5.0) Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
OLE: During 52 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities: OLE Phase
ParticipantsZavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)
Hemoglobin01
Neutrophils11
AST01
Creatine Kinase107
Glucose fasting, low10
LDL Cholesterol78
LDL Cholesterol, fasting44
LDL Cholesterol, not fasting11
Potassium, high02
Triglycerides11
Triglycerides, fasting01
Triglycerides, not fasting10
Urinalysis10
SecondaryPercentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: DBT Phase

Elevations of AST or alanine aminotransferase (ALT) \> 3 \*upper limit of normal (ULN) concurrent with total bilirubin (TBL) \> 2 \*ULN (elevations on the same laboratory collection date) were included.

Time frame:
DBT: Over 12 weeks of treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: DBT Phase
Percentage of participantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: DBT Phase0 (0.0 to 2.5)0 (0.0 to 2.5)0 (0.0 to 1.3)0 (0.0 to 5.0)0 (0.0 to 4.9)0 (0.0 to 2.5)
SecondaryPercentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: OLE Phase

Elevations of AST or ALT \> 3 \* ULN concurrent with TBL \> 2 \*ULN were defined as elevations on the same collection date.

Time frame:
OLE: Over 52 weeks of treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: OLE Phase
Percentage of participantsZavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)
Percentage of Participants With AST or ALT Elevations >3 * ULN With Total Bilirubin > 2 * ULN: OLE Phase0 (0.0 to 2.8)0 (0.0 to 3.0)
SecondaryNumber of Participants With Hepatic-related AEs by Intensity: DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

Time frame:
DBT Phase: During 12 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs by Intensity: DBT Phase
ParticipantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)
Mild101101
Moderate000101
Severe000000
SecondaryNumber of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

Time frame:
DBT Phase: During 12 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: DBT Phase
ParticipantsZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: DBT Phase000000
SecondaryNumber of Participants With Hepatic-related AEs by Intensity: OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. AEs by intensity: Mild: Transient and may require only minimal treatment or therapeutic intervention. Event did not interfere with activities of daily living. Moderate: Alleviated with additional specific therapeutic intervention. Event interfered with activities of daily living, causing discomfort, but possessed no significant or permanent risk of harm. Severe: Interrupted activities of daily living significantly affected clinical status or required intensive therapeutic intervention.

Time frame:
OLE: Over 52 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs by Intensity: OLE Phase
ParticipantsZavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)
Mild11
Moderate12
Severe01
SecondaryNumber of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.

Time frame:
OLE: Over 52 weeks of treatment
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: OLE Phase
ParticipantsZavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation: OLE Phase01

Adverse events

Collected over DBT Phase: 12 weeks of treatment; OLE Phase: 52 weeks of treatment; Follow-up phase: 8 weeks after the discontinuation or completion of treatment in DBT (if not entered OLE) or OLE phase. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant 100 mg (DBT)1/173 (0.6%)1/173 (0.6%)14/173 (8.1%)
Zavegepant 200 mg (DBT)0/175 (0%)1/175 (0.6%)8/175 (4.6%)
Zavegepant Pooled (DBT)0/348 (0%)2/348 (0.6%)22/348 (6.3%)
Placebo (DBT) Matched to Zavegepant 100 mg0/86 (0%)0/86 (0%)13/86 (15.1%)
Placebo (DBT) Matched to Zavegepant 200 mg0/88 (0%)1/88 (1.1%)11/88 (12.5%)
Placebo Pooled (DBT)0/174 (0%)1/174 (0.6%)24/174 (13.8%)
Zavegepant 100 mg (OLE)0/155 (0%)1/155 (0.6%)12/155 (7.7%)
Zavegepant 200 mg (OLE)0/143 (0%)3/143 (2.1%)12/143 (8.4%)
Zavegepant 100 mg DBT/Zavegepant 100 mg OLE: Follow-up0/154 (0%)0/154 (0%)0/154 (0%)
Zavegepant 200 mg DBT/ Zavegepant 200 mg OLE: Follow-up0/162 (0%)1/162 (0.6%)0/162 (0%)
Placebo Matched to Zavegepant 100 mg (DBT)/ Zavegepant 100 mg OLE: Follow-up0/47 (0%)1/47 (2.1%)0/47 (0%)
Placebo Matched to Zavegepant 200 mg (DBT)/ Zavegepant 200 mg OLE: Follow-up0/48 (0%)0/48 (0%)0/48 (0%)
Placebo Pooled (DBT)/No Zavegepant OLE: Follow-up0/70 (0%)0/70 (0%)0/70 (0%)
Most frequent serious events
Most frequent serious events
EventZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)Zavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)Zavegepant 100 mg DBT/Zavegepant 100 mg OLE: Follow-upZavegepant 200 mg DBT/ Zavegepant 200 mg OLE: Follow-upPlacebo Matched to Zavegepant 100 mg (DBT)/ Zavegepant 100 mg OLE: Follow-upPlacebo Matched to Zavegepant 200 mg (DBT)/ Zavegepant 200 mg OLE: Follow-upPlacebo Pooled (DBT)/No Zavegepant OLE: Follow-up
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1730/1750/3480/860/880/1740/1550/1430/1540/1621/470/480/70
CholecystitisHepatobiliary disorders0/1730/1750/3480/860/880/1740/1552/1430/1540/1620/470/480/70
COVID-19Infections and infestations0/1730/1750/3480/861/881/1740/1550/1430/1540/1620/470/480/70
Intestinal obstructionGastrointestinal disorders0/1730/1750/3480/860/880/1740/1551/1430/1540/1620/470/480/70
Lung disorderRespiratory, thoracic and mediastinal disorders0/1730/1750/3480/860/880/1740/1551/1430/1540/1620/470/480/70
NephrolithiasisRenal and urinary disorders0/1730/1750/3480/860/880/1741/1550/1430/1540/1620/470/480/70
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/1730/1750/3480/860/880/1740/1550/1430/1541/1620/470/480/70
Hypertensive heart diseaseCardiac disorders1/1730/1751/3480/860/880/1740/1550/1430/1540/1620/470/480/70
Iron deficiency anaemiaBlood and lymphatic system disorders0/1731/1751/3480/860/880/1740/1550/1430/1540/1620/470/480/70
Most frequent other events
Most frequent other events
EventZavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Zavegepant Pooled (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgPlacebo Pooled (DBT)Zavegepant 100 mg (OLE)Zavegepant 200 mg (OLE)Zavegepant 100 mg DBT/Zavegepant 100 mg OLE: Follow-upZavegepant 200 mg DBT/ Zavegepant 200 mg OLE: Follow-upPlacebo Matched to Zavegepant 100 mg (DBT)/ Zavegepant 100 mg OLE: Follow-upPlacebo Matched to Zavegepant 200 mg (DBT)/ Zavegepant 200 mg OLE: Follow-upPlacebo Pooled (DBT)/No Zavegepant OLE: Follow-up
NauseaGastrointestinal disorders12/1735/17517/3488/865/8813/1740/1550/1430/1540/1620/470/480/70
COVID-19Infections and infestations0/1730/1750/3480/860/880/17412/15512/1430/1540/1620/470/480/70
Urinary tract infectionInfections and infestations2/1731/1753/3486/861/887/1740/1550/1430/1540/1620/470/480/70
DiarrhoeaGastrointestinal disorders1/1732/1753/3481/865/886/1740/1550/1430/1540/1620/470/480/70

Baseline characteristics

DBT safety analysis set included participants in the safety analysis set who took greater than or equal to (\>=) 1 dose of DB study drug (zavegepant or placebo), i.e., nonmissing DB study drug start date.

Age, Continuous
Age, Continuous(Years)Zavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgTotal
Mean41.7 ± 12.8543.2 ± 13.3041.7 ± 13.1541.5 ± 13.1442.2 ± 13.09
Sex: Female, Male
Sex: Female, Male(Participants)Zavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgTotal
Female1271447270413
Male46311418109
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgTotal
Hispanic or Latino48472627148
Not Hispanic or Latino1251286061374
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zavegepant 100 mg (DBT)Zavegepant 200 mg (DBT)Placebo (DBT) Matched to Zavegepant 100 mgPlacebo (DBT) Matched to Zavegepant 200 mgTotal
American Indian or Alaska Native00011
Asian423514
Native Hawaiian or Other Pacific Islander02013
Black or African American35351617103
White1301326663391
More than one race44109
Unknown or Not Reported00011
08

Study locations

116 sites
  • Xenoscience, Inc
    Phoenix, Arizona 85004, United States
  • Tucson Neuroscience Research
    Tucson, Arizona 85710, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Axiom Research, Llc
    Colton, California 92324, United States
  • Wr-Pri, Llc
    Encino, California 91316, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Research, LLC.
    Long Beach, California 90806, United States
  • Clinical Research Institute
    Los Angeles, California 90048, United States
  • Wr-Pri, Llc
    Newport Beach, California 92660, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • California Neuroscience Research Medical Group, inc.
    Sherman Oaks, California 91403, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Ki Health Partners, LLc, dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Neurology Offices of South Florida
    Boca Raton, Florida 33428, United States
  • Accel Research Sites Network - Edgewater Clinical Research Unit
    Edgewater, Florida 32132, United States
  • Complete Health Research
    Edgewater, Florida 32132, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • AppleMed Research Group, LLC
    Miami, Florida 33126, United States
  • AppleMed Research Group, LLC
    Miami, Florida 33155, United States
  • Brainstorm Research
    Miami, Florida 33176, United States
  • The Neurology Research Group
    Miami, Florida 33176, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Complete Health Research
    Ormond Beach, Florida 32174, United States
  • Ideal Clinical Research
    Pembroke Pines, Florida 33026, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060, United States
  • Accel Research Sites Network - St. Petersburg Clinical Research Unit
    Saint Petersburg, Florida 33709, United States
  • Clin-Med Research & Development LLC
    South Miami, Florida 33143, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • JSV Clinical Research Study Inc
    Tampa, Florida 33634, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Clinical Investigation Specialists, Inc.
    Gurnee, Illinois 60031, United States
  • Clinical Investigation Specialists, Inc
    Gurnee, Illinois 60031, United States
  • MediSphere Medical Research Center, LLC.
    Evansville, Indiana 47714, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Meridian Clinical Research, LLC
    Sioux City, Iowa 51106, United States
  • Alliance for Multispecialty Reseach, LLC
    El Dorado, Kansas 67042, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Collevtive Medical Research
    Overland Park, Kansas 66210, United States
  • Kansas Institute of Research
    Overland Park, Kansas 66211, United States
  • The Research Group of Lexington, Llc.
    Lexington, Kentucky 40503, United States
  • The Research Group of Lexington, Llc
    Lexington, Kentucky 40503, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Crescent City Headache and Neurology Center
    Chalmette, Louisiana 70043, United States
  • Alliance for Multispecialty Research, LLC.
    New Orleans, Louisiana 70119, United States
  • DelRicht Research
    New Orleans, Louisiana 70124, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Neurology Center of New England P.C.
    Foxboro, Massachusetts 02035, United States
  • Community Clinical Research Network Inc
    Marlborough, Massachusetts 01752, United States
  • MedVadis Research Corporation
    Waltham, Massachusetts 02451, United States
  • Michigan Head Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Romedica LLC
    Rochester, Michigan 48307, United States
  • Alliance for Multispecialty Reseach, LLC
    Kansas City, Missouri 64114, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65807, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65810, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Excel Clinical research
    Las Vegas, Nevada 89109, United States
  • Wr-Crcn, Llc
    Las Vegas, Nevada 89118, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Dent Neurosciences Research Center, Inc.
    Amherst, New York 14226, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • New York Neurology Associates
    New York, New York 10003, United States
  • Fieve Clinical Research, Inc
    New York, New York 10017, United States
  • North Suffolk Neurology, PC
    Port Jefferson Station, New York 11776, United States
  • Upstate Clinical Research Associates, LLC
    Williamsville, New York 14221, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • Accellacare
    Raleigh, North Carolina 27609, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • Carolina Research Center, Inc.
    Shelby, North Carolina 28150, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • WellNow Urgent Care and Research
    Cincinnati, Ohio 45215, United States
  • Wellnow Urgent Care
    Cincinnati, Ohio 45215, United States
  • Hometown Urgent Care and Research
    Columbus, Ohio 43214, United States
  • Wellnow Urgent Care and Research
    Columbus, Ohio 43214, United States
  • Hometown Urgent Care and Research
    Dayton, Ohio 45424, United States
  • WellNow Urgent Care and Research
    Dayton, Ohio 45424, United States
  • Neuro-Behavioral Clinical Research, Inc.
    North Canton, Ohio 44720, United States
  • WellNow Urgent Care and Research
    Troy, Ohio 45373, United States
  • Hightower Clinical
    Oklahoma City, Oklahoma 73102, United States
  • Hightower Clinical
    Oklahoma City, Oklahoma 73134, United States
  • Summit Headlands LLC, dba Summit Research
    Portland, Oregon 97210, United States
  • Clinical Research Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Preferred Primary Care Physicians, Inc.
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Reading Hospital Clinical Trials Office
    West Reading, Pennsylvania 19611, United States
  • Tower Health Medical Group - Neurology
    West Reading, Pennsylvania 19611, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Accellacare (Administrative Only)
    Bristol, Tennessee 37620, United States
  • Internal Medicine and Pediatric Associates of Bristol, PC
    Bristol, Tennessee 37620, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • KCA Neurology, PLLC
    Franklin, Tennessee 37067, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States

Showing the first 100 of 116 sites. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Mar 2024, 35 months.

Results were first posted in Mar 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 18, 2021
StartActual
Mar 26, 2021
Primary completionActual
Mar 21, 2024
CompletionActual
Mar 21, 2024
Results first posted
Mar 27, 2025
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04804033
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Mar 26, 2021
Primary completion
Mar 21, 2024
Completion
Mar 21, 2024
Results posted
Mar 27, 2025
Last update
Mar 27, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion